40 Patents. 10-Year Exclusivity. The Complete Value Chain.
Anjaniputra's competitive advantage is not infrastructure — it is intellectual property. By securing a 10-year strategic moat through exclusive ownership across four critical layers, we have created India's most defensible position in chronic disease medicine.
Why This Matters
Without the IP, a facility is just a cafeteria. With the IP, the cafeteria becomes a clinical delivery system for metabolic regulation. Anjaniputra's 40 licensed patents are not theoretical — they are the barrier that prevents Apollo, KIMS, or any competitor from replicating what we do. To access these protocols, they will ultimately need to come to us.
A 10-Year Strategic Moat
Each layer of ownership reinforces the others — creating a complete, self-reinforcing competitive position.
Treatment
Exclusive rights to execute proprietary algorithm-driven protocols in India. Competitors cannot legally replicate procedures.
No other Indian hospital — including Apollo or KIMS — can legally offer these clinical protocols. The treatment rights create a permanent, legally-protected clinical moat.
Distribution
Sole authority to supply technology, devices, and supplements. Our pharmacy requires CEO-level authorization for product sale.
Our proprietary supplement and device line cannot be obtained through any other Indian supplier. Distribution exclusivity ensures complete commercial control.
Research
Mandate to refine global science within Indian incubators — IIT Hyderabad, CCMB, C-CAMP — for CDSCO compliance.
Our research mandate ensures that global technologies are continuously refined, validated, and domesticated for the Indian regulatory environment.
Manufacturing
Future-state domestic production of pharma and biotech assets — full supply chain sovereignty.
Long-term infrastructure for domestic production eliminates supply chain vulnerability and creates a new revenue stream from pharmaceutical and biotech manufacturing.
Seven Technologies. One Algorithm.
Each exclusive technology transfer adds a critical layer to the chronic disease algorithm.
| Partner | Country |
|---|---|
| CureSpec / Medispec | Israel |
| RGCC | Switzerland |
| Aroa Biosurgery | New Zealand |
| European Biomedical Group | Germany |
| NHS UK | United Kingdom |
| NaviPoint Health | USA |
| SRAM MRAM | UK / Global |
Whether you are seeking answers for a chronic condition or exploring regenerative medicine — we have a pathway for you.
Our care team is ready to match you with the right specialist and the world's most advanced treatment protocol.